Detalhes do Documento

Prodrugs for the treatment of neglected diseases

Autor(es): Chin, Chung Man [UNESP] ; Ferreira, Elizabeth Igne ; Santos, Jean Leandro [UNESP] ; Giarolla, Jeanine ; Rando, Daniela Goncales ; Almeida, Adelia Emilia de [UNESP] ; Bosquesi, Priscila Longhin [UNESP] ; Menegon, Renato Farina [UNESP] ; Blau, Lorena [UNESP]

Data: 2014

Identificador Persistente: http://hdl.handle.net/11449/7916

Origem: Oasisbr

Assunto(s): tropical neglected diseases; prodrug design; American trypanosomisasis; African trypanosomiasis; malaria; sickle cell disease; tuberculosis; leishmaniasis; schistosomiasis; tropical neglected diseases; tropical neglected diseases; prodrug design; prodrug design; American trypanosomisasis; American trypanosomisasis; African trypanosomiasis; African trypanosomiasis; malaria; malaria; sickle cell disease; sickle cell disease; tuberculosis; tuberculosis; leishmaniasis; leishmaniasis; schistosomiasis; schistosomiasis


Descrição

Made available in DSpace on 2013-08-28T14:08:23Z (GMT). No. of bitstreams: 1 WOS000254464700011.pdf: 472377 bytes, checksum: da925e8d298894bda28d95c67df8763a (MD5)

Made available in DSpace on 2013-09-30T18:06:51Z (GMT). No. of bitstreams: 2 WOS000254464700011.pdf: 472377 bytes, checksum: da925e8d298894bda28d95c67df8763a (MD5) WOS000254464700011.pdf.txt: 144373 bytes, checksum: dbe0aa780106d538e3078522b0597b02 (MD5) Previous issue date: 2008-03-01

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-20T13:25:01Z No. of bitstreams: 2 WOS000254464700011.pdf: 472377 bytes, checksum: da925e8d298894bda28d95c67df8763a (MD5) WOS000254464700011.pdf.txt: 144373 bytes, checksum: dbe0aa780106d538e3078522b0597b02 (MD5)

Made available in DSpace on 2014-05-20T13:25:01Z (GMT). No. of bitstreams: 2 WOS000254464700011.pdf: 472377 bytes, checksum: da925e8d298894bda28d95c67df8763a (MD5) WOS000254464700011.pdf.txt: 144373 bytes, checksum: dbe0aa780106d538e3078522b0597b02 (MD5) Previous issue date: 2008-03-01

Recently, World Health Organization ( WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [ 3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease ( American trypanosomiasis), sleeping sickness ( African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.

UNESP Rodovia Araraquara, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, Lapdesf Lab Desenvolvimento Farmacos, BR-14801902 São Paulo, Brazil

USP SP, Fac Ciencias Farmaceut, Dept Farm, LAPEN Lab Planejamento & Sintese Quimioterap Pote, BR-05508900 São Paulo, Brazil

UNESP Rodovia Araraquara, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, Lapdesf Lab Desenvolvimento Farmacos, BR-14801902 São Paulo, Brazil

Tipo de Documento Artigo científico
Idioma Inglês
facebook logo  linkedin logo  twitter logo 
mendeley logo

Documentos Relacionados

Não existem documentos relacionados.